drugset / Trial / NCT00434681

Paracetamol Oral Paediatric Suspension at 4.8% : Study of Acceptability and Safety.

NCT00434681

Phase 3 Completed 48 enrolled Sanofi
Non-randomizedSingle-groupOpen-label

Summary

Evaluate the acceptability over 24 hours of a new paracetamol formulation 4.8% paediatric oral suspension in children weighing between 3 and 26 kg including limits

Timeline

Start
2006-10
Primary completion
Completion
2007-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetaminophen Small molecule 4.8 % Oral

Indications

No indication recorded.